With the end of the results disclosure of the three quarterly reports, there are less than two months to go before 2022, and the annual report notice also kicked off at the same time. In the A-share market, the disclosure of the annual report performance notice has become one of the focuses of the market.
Data show that as of November 25, a total of 50 A-share listed companies have issued 2021 performance forecasts. Among them, pre-Xi companies account for nearly 80%, and six companies expect the largest increase in net profit for the whole year to exceed 100%.
50 companies disclose annual report notice
Specifically, among the 50 companies that have announced their annual reports, 21 listed companies have slightly increased, 13 listed companies have increased in advance, and 5 listed companies have continued to make profits, accounting for nearly 80% of the total.
In terms of the increase in net profit in the annual report, six of the companies in the above annual report are expected to make a net profit of more than 100% compared with the same period last year, including Ai Yatong, Yan'an Bikang, Hualan shares, Pran shares, Longhua New Materials and Zali Pharmaceutical Co., Ltd.; the median increase in net profit of Yuean New Materials, Gale shares and focus Media fell at 50%, 100%.
From the upper limit of net profit, focus Media, Gale shares, Jinjia shares, Yan'an Bikang are in the forefront, with an annual net profit of more than 1 billion yuan. Gale, for example, expects net profit of 4.244 billion yuan to 4.528 billion yuan in 2021, up 49% to 59% from a year earlier.
As for the change in performance, the company said it had improved profitability due to increased sales of products such as VR virtual reality, smart wearable and smart wireless headphones.
From the point of view of the company's market capitalization, among the listed companies that forecast the performance in 2021, only Gale shares and focus Media are the latest ones with a market capitalization of more than 100 billion yuan.
Focus Media expects net profit of 6.02 billion yuan to 6.2 billion yuan in 2021, up 50.36% from a year earlier to 54.85%. The company's performance has maintained a steady growth trend in the field of consumer goods; it has benefited from the base effect, so the annual operating performance has increased by a large margin compared with the same period last year.
From an industry point of view, the companies that disclose the annual report forecast are concentrated in medicine and biology, machinery and equipment, chemical industry, electronics and other industries.
Net profit of 6 companies increased by more than 100%
Specific to individual stocks, Yiyatong is expected to be attributed to shareholders' net profit of 510 million yuan to 550 million yuan for the whole year, an increase of 313.16% to 345.56% over the same period last year.
Yiyatong is a leader in the domestic supply chain industry, mainly engaged in supply chain management services, including breadth supply chain business, deep supply chain business and logistics platform business.
For the substantial increase in performance, the company said that vigorously promote the adjustment of business structure, brand operation and marketing business accounted for an increasing proportion. The company completed the non-public offering of new shares in July to optimize the financing structure and effectively reduce financing costs.
Hualan shares is expected to achieve a net profit of about 197 million yuan to 266 million yuan attributed to the owner of the parent company in 2021, an increase of about 141.64% to 226.92% over the same period in 2020, ranking second on the pre-added list.
Hualan Co., Ltd. is the first manufacturer of pharmaceutical packaging materials to obtain the registration certificate for the production of film-coated rubber plugs in China. It is mainly engaged in the research, production and marketing of pharmaceutical packaging materials for injections, and its main products include film-coated rubber plugs and conventional rubber plugs, which are the main suppliers of rubber plugs for vaccines in China.
Pran shares are new shares listed in Science and Technology Innovation Board this year. The company expects full-year net profit of 187 million yuan to 253 million yuan, an increase of 117.34% to 194.05% over the same period last year, ranking third on the pre-addition list.
Puran is one of the most important providers of memory chips in China. Mainly engaged in the design and sales of non-volatile memory chips, the main products include NORFlash and EEPROM two types of general-purpose chips.
For the substantial increase in performance, the company said that it is mainly through research and development to achieve the upgrading of the process, mass production of new products and iteration of the original products, to enhance the competitiveness of the products. At the same time, the global semiconductor industry continues to thrive, resulting in a shortage of products.
Yan'an Bikang expects to achieve a net profit of about 950 million-1 billion yuan in 2021, compared with a net profit loss of 1.071 billion yuan in the same period last year. It is not difficult to see that Yan'an Bikang will achieve a substantial turnaround in 2021.
For the big increase in performance, the company said it was mainly due to the increase in the price of lithium hexafluorophosphate.
Longhua Xincai expects to achieve a net profit of about 223.53 million to 247.06 million in 2021, an increase of 91.98 per cent to 112.19 per cent over the same period last year.
Zali Pharmaceutical expects the net profit attributable to shareholders of listed companies to be 170 million yuan to 187 million yuan in 2021, an increase of 91.44-110.58% over the same period last year. It also means that this year's performance of Xili Pharmaceutical will be the best in history.
Zali Pharmaceutical Co., Ltd. is mainly engaged in the research, production and marketing of a series of products of medicinal fungi Wuling and bailing, pieces of traditional Chinese medicine and granules of traditional Chinese medicine formula. In addition to the main business of proprietary Chinese medicine, Zali Pharmaceutical has also entered the chemical medicine racetrack. Its polycarbopol calcium tablets (to improve diarrhea and constipation) are potential chemical drugs for gastrointestinal diseases, as well as a stake in Keji Pharmaceutical Co., Ltd., which has made a lot of gains.
The performance of the pre-rights issue is eye-catching.
It is worth mentioning that the performance is expected to double shares up an average of more than 40 per cent so far this year, outperforming the Prev. From the perspective of individual stocks, the biggest gain so far this year is Yan'an Bikang, up more than 150%.
On the contrary, the performance pre-loss stock market does not perform well. Beriki expects a full-year net profit loss of 60 million yuan to 90 million yuan, compared with a profit of 211 million yuan in the same period last year, turning into a loss over the same period last year. The stock has been weak this year and its share price has halved so far.
From the point of view of the latest price compared with the agency's unanimous forecast target price, the share prices of four listed companies, including Zhuoran shares, focus Media, Yi Yatong and Xindian Software, have all risen by more than 20%.
Industry insiders agree that since the beginning of this year, the overall market index is in the process of a narrow range of shocks, while many high-quality leading stocks have been mistakenly killed. With the successive release of the annual report, the market has entered the performance verification period, and the capital will pay more attention to the annual report, which can focus on the high-growth companies in the main business.
It should be noted, however, that performance is an important factor in supporting share prices, but not the only one. Yan'an Bikang's performance, for example, is still up in advance, but has fallen by more than 20% since November. It is mainly affected by the problems such as the occupation of funds by the controlling shareholders of listed companies, the payment of bonds, letter irregularities and so on.
Overall, performance is an important factor in supporting stock prices, but not the only one. Investors also need to make a comprehensive evaluation of the company from many aspects according to the fundamentals of the company, the industry level and the company level.